Contract Pharma: What are the major problems with biopharma sampling, the way it is traditionally done today…both with the mechanics, and also the statistics, modeling.  How does that affect the ability to control processes? Clint Pepper: There are three primary issues seen in bioreactor autosampling. The first is loss of bioreactor sterility. Running bioreactors is an expensive and time-consuming process. Even rare sterility loss events have significant impact on a facility’s budget and timelin...